ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Further studies on compound BCR-ABL mutations, specifically resistance to 2nd and 3rd generation TKI resistance, by employing genomic techniques will lead to better clinical management of recent challenges in CML treatment (Hochhaus et al., 2020; Soverini et al., 2020).